Nutanix appoints former Broadcom CFO Eric Brandt to board; David Humphrey resigns

Nutanix, Inc.

Eric K. Brandt appointed to Nutanix board effective May 15, 2025.
Brandt served as Broadcom CFO (2007-2016) and held CEO/CFO roles at Avanir and Allergan.
David Humphrey (Bain Capital partner) resigned effective same date; no disagreement with company.
Max de Groen, also a Bain Capital partner, will continue serving on the board.
Brandt will receive standard non-employee director compensation and enter indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Humphrey

director

NTNX · Nutanix, Inc.

Effective: 2025-05-15
Filed: May 16, 2025, 7:59 PM ET

David Humphrey submitted his resignation as a director, effective as of May 15, 2025.

Appointed

Eric K. Brandt

director

NTNX · Nutanix, Inc.

Effective: 2025-05-15
Filed: May 16, 2025, 7:59 PM ET

appointed Eric K. Brandt as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Humphrey resigned as director at Nutanix, Inc..

Action: resigned
Role: director

Exact text from the filing

David Humphrey submitted his resignation as a director, effective as of May 15, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric K. Brandt was appointed as director at Nutanix, Inc..

Action: appointed
Role: director

Exact text from the filing

appointed Eric K. Brandt as a director.

View on SEC.gov

Nutanix, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-073565

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.